Skip to search boxSkip to navigationSkip to main content

W246G Mutant ELOVL4 Impairs Synaptic Plasticity in Parallel and Climbing Fibers and Causes Motor Defects in a Rat Model of SCA34

  • Raghavendra Y. Nagaraja
    ,
  • David M. Sherry
    ,
  • Jennifer L. Fessler
    ,
  • Megan A. Stiles
    ,
  • Feng Li
    ,
  • Karanpreet Multani
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Spinocerebellar ataxia (SCA) is a neurodegenerative disorder characterized by ataxia and cerebellar atrophy. A number of different mutations gives rise to different types of SCA with characteristic ages of onset, symptomatology, and rates of progression. SCA type 34 (SCA34) is caused by mutations in ELOVL4 (ELOngation of Very Long-chain fatty acids 4), a fatty acid elongase essential for biosynthesis of Very Long Chain Saturated and Polyunsaturated Fatty Acids (VLC-SFA and VLC-PUFA, resp., ≥28 carbons), which have important functions in the brain, skin, retina, Meibomian glands, testes, and sperm. We generated a rat model of SCA34 by knock-in of the SCA34-causing 736T>G (p.W246G) ELOVL4 mutation. Rats carrying the mutation developed impaired motor deficits by 2 months of age. To understand the mechanism of these motor deficits, we performed electrophysiological studies using cerebellar slices from rats homozygous for W246G mutant ELOVL4 and found marked reduction of long-term potentiation at parallel fiber synapses and long-term depression at climbing fiber synapses onto Purkinje cells. Neuroanatomical analysis of the cerebellum showed normal cytoarchitectural organization with no evidence of degeneration out to 6 months of age. These results point to ELOVL4 as essential for motor function and cerebellar synaptic plasticity. The results further suggest that ataxia in SCA34 patients may arise from a primary impairment of synaptic plasticity and cerebellar network desynchronization before onset of neurodegeneration and progression of the disease at a later age.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 4921-4943 (23 pages)

Journal (Volume, Issue Number)

Molecular Neurobiology (Volume 58, Issue 10)

Publication milestones

  • Published - 10/2021

Publication status

Published - 10/2021

ISSN

0893-7648

Publication IDs

  • Scopus: 85109308128
  • PubMed: 34227061

Publication metrics

Metrics

Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
18
Citation count
16
Mentions
2

Funding Details

Supported by a Multi-PI Team Science grant from the Presbyterian Health Foundation (DMS, REA, and MPA). NIH grants R01EY04149, P30EY021725, and R21NS090117 (REA) and unrestricted grant support from Research to Prevent Blindness to Dr. Gregory Skuta at the Dean McGee Eye Institute. NIH grants R01 EY030513 and R21 AR076035 and the Oklahoma Center for Advancement of Science and Technology (OCAST) (MPA). Research reported in this publication was supported in part by 1P20GM125528 “Cellular and Molecular GeroScience CoBRE” from the National Institute of General Medical Sciences, 3P30AG050911-04S1, NIH grant R01 AG062655 (FD) and a supplement grant to Oklahoma Nathan Shock Center (FD), and by an Oklahoma Center for Adult Stem Cell Research shared equipment grant (DMS). The monoclonal antibodies against VGluT1 (clone N28/9), GluA1 (clone N355/1), GluA2 (clone L21/32), and PSD-95 (clone 75-028) were developed by and/or obtained from the UC Davis/NIH NeuroMab Facility, supported by NIH grant U24NS050606 and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616. The synaptotagmin 2 monoclonal antibody generated by Trevarrow et al. [] was obtained from the Zebrafish International Resource Center, which is supported by grant P40RR012546 from the NIH-NCRR. We thank Drs. Anna Csiszar, Tamas Kiss, and Zoltan Ungvari and the Oklahoma Nathan Shock Center for advice on the behavioral assessment. We are grateful to Dr. Blake Hopiavuori and Nicole A. Rocha-Hopiavuori for the programming help with data extraction and analysis of the spontaneous cerebellar network activity. The monoclonal antibodies against VGluT1 (clone N28/9), GluA1 (clone N355/1), GluA2 (clone L21/32), and PSD-95 (clone 75-028) were developed by and/or obtained from the UC Davis/NIH NeuroMab Facility, supported by NIH grant U24NS050606 and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616. The synaptotagmin 2 monoclonal antibody generated by Trevarrow et al. [92] was obtained from the Zebrafish International Resource Center, which is supported by grant P40RR012546 from the NIH-NCRR. We thank Drs. Anna Csiszar, Tamas Kiss, and Zoltan Ungvari and the Oklahoma Nathan Shock Center for advice on the behavioral assessment. We are grateful to Dr. Blake Hopiavuori and Nicole A. Rocha-Hopiavuori for the programming help with data extraction and analysis of the spontaneous cerebellar network activity.
FundersFunding numbers
DMS
-
PHF
-
Oklahoma Center for Adult Stem Cell Research
-
UC Davis/NIH NeuroMab
-
REA
-
Zoltan Ungvari
-
Oklahoma Nathan Shock Center
-
NIH/NCRR
-
RPB
R21 AR076035, R01 EY030513
NIGMS
P20GM125528, 3P30AG050911-04S1
NIAMS
R21AR076035
OCAST
1P20GM125528
NINDS
U24NS050606
NIH
R21NS090117, R01EY04149
NCI
P01CA095616
NCRR
P40RR012546
NEI
P30EY012190, P30EY021725, R01EY030513
NIA
R01AG062655